• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

    11/13/25 8:30:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    • As a leader in migraine treatment, AbbVie is committed to addressing the impact of migraine in the workplace.
    • 2025 honorees represent a diverse group of achievers—from teachers and authors to small business owners and aspiring yoga and meditation instructors—each redefining success while living with migraine.
    • Presenteeism accounts for nearly 90% of migraine-related productivity loss, impacting careers, finances, and overall well-being.1

    NORTH CHICAGO, Ill., Nov. 13, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the 20 recipients of its second annual AbbVie Migraine Career Catalyst Award™ contest, an initiative that helps people living with migraine pursue their career and professional development goals. Each winner received $2,500 in financial support to invest in opportunities that advance their aspirations, from continued education and training to creating healthier, more supportive work environments.

    Migraine affects one in six people and is present in nearly every workplace. Still, despite its widespread impact and significant costs, awareness and understanding remain limited. Amid these challenges, many people living with migraine continue to redefine what is possible, showing remarkable resilience and advocacy in both their personal and professional lives.

    The contest drew entries from across the United States, with winners representing a broad mix of professions and life stages. Despite the challenges that migraine often presents, each recipient shared a powerful story of resilience, ambition, and commitment to advancing their professional goals. Among the 20 awardees, several shared reflections on what the recognition means to them and how it will help shape their professional paths:

    • "Receiving the AbbVie Migraine Career Catalyst Award is not just a financial boost; it's a profound validation of my resilience," said Debbie D., a user interface designer from California who has lived with migraine for more than 40 years and experienced significant stigma in the office. "However, the award shows that my ambition is seen and supported, offering the tools I need to thrive and advance my career without compromising my health. Most importantly, it empowers me to be a visible example to others that it is truly possible to succeed despite migraine."



    • "I sat in the teacher's lounge when it hit—my skull tightened, pressure crushing. The words on my computer blurred, my vision fracturing into bursts of color. Stars danced in the corners of my sight," wrote Garcie C., an educator from Massachusetts who lives with Chronic Migraine. "Winning the AbbVie Migraine Career Catalyst Award means so much to me because it honors not only my journey but also the collective experiences of women navigating motherhood, migraine disability, and work within systems not designed for our realities."



    • "This award marks the beginning of a new chapter, one filled with purpose and possibility," said Laura M., a communicator and designer from Indiana whose migraine attacks disrupted her plans to attend law school. "I am grateful for the opportunity to build a career that aligns with who I am while navigating life with migraine."

    Many people with migraine continue to face stigma, bias and insufficient support in their professional lives.2 The AbbVie Migraine Career Catalyst Award contest was created to help close this gap, providing recognition, resources, and visibility for individuals whose careers have been disrupted by migraine. By supporting their goals, AbbVie is helping to foster greater understanding of the realities of living and working with migraine.

    "AbbVie is helping shift how workplaces and society understand migraine, while empowering individuals to thrive and pursue their goals," said Jag Dosanjh, senior vice president, AbbVie, and president, neuroscience and eye care. "We recognize that migraine doesn't just interrupt workdays, it can alter career trajectories. We're proud to be the only company to offer three treatment options that address the spectrum of migraine and we are continuing to research and drive innovation to uncover new therapies that can help people living with this debilitating disease."

    For the complete list of 2025 winners, visit www.migrainecareercatalyst.com.

    About AbbVie in Migraine

    AbbVie is the only company with three prescription treatments designed to meet patient needs across the full spectrum of migraine to help patients living with this debilitating disease. However, our commitment to the community goes beyond medicine. Through our research and partnerships with the migraine community – including patients, healthcare providers, and advocacy organizations – AbbVie has a deep understanding of the challenges that people living with migraine can face in the workplace. The AbbVie Migraine Career Catalyst Award contest is an extension of this commitment, empowering people living with migraine to pursue their professional objectives.

    About AbbVie

    AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – as well as products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

    Media Contact:

    Jacqueline Karis

    +1 (310) 486-4993

    [email protected] 

    References:

    1. Begasse de Dhaem O, Sakai F. Migraine in the workplace. eNeurologicalSci. 2022;27:100408. doi: 10.1016/j.ensci.2022.100408
    2. Migraine At Work. About. Accessed September 26, 2025. https://migraineatwork.org/about/

    US-NEUM-250114 11/25

    AbbVie logo

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-announces-20-recipients-of-migraine-career-catalyst-award-302613759.html

    SOURCE AbbVie

    Get the next $ABBV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    11/13/2025$280.00Sector Outperform
    Scotiabank
    11/4/2025$237.00Buy → Hold
    DZ Bank
    10/14/2025Buy → Hold
    Erste Group
    10/1/2025Buy → Hold
    HSBC Securities
    9/17/2025$270.00Hold → Buy
    Berenberg
    8/12/2025$231.00Overweight
    Piper Sandler
    8/7/2025$214.00Neutral → Outperform
    Daiwa Securities
    5/14/2025$205.00Buy → Neutral
    Citigroup
    More analyst ratings

    $ABBV
    SEC Filings

    View All

    SEC Form 10-Q filed by AbbVie Inc.

    10-Q - AbbVie Inc. (0001551152) (Filer)

    11/4/25 2:05:49 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    10/31/25 7:51:43 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    10/3/25 4:09:03 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer

    Film captures inspiring journeys of three individuals living with chronic lymphocytic leukemia (CLL)CLL is one of the most common leukemias among adults affecting more than 200,000 people in the United States1,2Film premiered yesterday in Los Angeles, hosted by actor and advocate Jesse Tyler FergusonNow available on LA Times Studio Short Docs, AbbVie U.S. YouTube Channel; streaming on Documentary+ in DecemberNORTH CHICAGO, Ill., Nov. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today the launch of Second Winds, a new short film that captures the powerful, deeply personal journeys of three people living with chronic lymphoma leukemia (CLL), a common type of blood cancer effecting hun

    11/14/25 12:30:00 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

    As a leader in migraine treatment, AbbVie is committed to addressing the impact of migraine in the workplace. 2025 honorees represent a diverse group of achievers—from teachers and authors to small business owners and aspiring yoga and meditation instructors—each redefining success while living with migraine.Presenteeism accounts for nearly 90% of migraine-related productivity loss, impacting careers, finances, and overall well-being.1NORTH CHICAGO, Ill., Nov. 13, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the 20 recipients of its second annual AbbVie Migraine Career Catalyst Award™ contest, an initiative that helps people living with migraine pursue their career and professiona

    11/13/25 8:30:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

    - A total of 17 abstracts, including three accepted for presentation in the Cosmetic "Top Ten" Session, underscore Allergan Aesthetics' global industry leadership across multiple aesthetic categories - Oral abstract presentations include Phase 3 clinical study results for first-in-class botulinum neurotoxin serotype E (trenibotulinumtoxinE) and results from a Phase 4 study evaluating natural outcomes and patient satisfaction in a diverse population following use of 64 units of BOTOX® Cosmetic (onabotulinumtoxinA) for treatment of upper facial lines - Expert panel discussion explores new Hyaluronic Acid Injectable Fillers Report, along with current use, facts, and real-world satisfaction data

    11/12/25 8:30:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Quaggin Susan E

    4 - AbbVie Inc. (0001551152) (Issuer)

    10/2/25 5:00:41 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Alpern Robert J

    4 - AbbVie Inc. (0001551152) (Issuer)

    10/2/25 5:00:17 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Rapp Edward J

    4 - AbbVie Inc. (0001551152) (Issuer)

    10/2/25 5:00:12 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on AbbVie with a new price target

    Scotiabank initiated coverage of AbbVie with a rating of Sector Outperform and set a new price target of $280.00

    11/13/25 9:11:54 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie downgraded by DZ Bank with a new price target

    DZ Bank downgraded AbbVie from Buy to Hold and set a new price target of $237.00

    11/4/25 7:41:18 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie downgraded by Erste Group

    Erste Group downgraded AbbVie from Buy to Hold

    10/14/25 8:41:30 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Leadership Updates

    Live Leadership Updates

    View All

    AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

    Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

    2/14/25 7:40:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    Financials

    Live finance-specific insights

    View All

    AbbVie Reports Third-Quarter 2025 Financial Results

    Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results Include an Unfavorable Impact of $1.50 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers Third-Quarter Net Revenues of $15.776 Billion, an Increase of 9.1 Percent on a Reported Basis or 8.4 Percent on an Operational Basis Third-Quarter Global Net Revenues from the Immunology Portfolio Were $7.885 Billion, an Increase of 11.9 Percent on a Reported Basis, or 11.2 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.708 Billion; Global Rinvoq Net Revenues Were $2.184 Billion; Global Humira Net Revenues

    10/31/25 7:49:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Host Third-Quarter 2025 Earnings Conference Call

    NORTH CHICAGO, Ill., Oct. 2, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas –

    10/2/25 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.64 per share.   The cash dividend is payable November 14, 2025, to stockholders of record at the close of business on October 15, 2025.  Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We

    9/5/25 9:07:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/13/24 4:55:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    1/25/24 4:59:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/9/23 10:54:46 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care